The latest data demonstrate that the combination regimen delivers high response rates, durable progression-free survival benefits, and a favorable safety profile in patients with R/R marginal zone lymphoma (MZL) and R/R follicular lymphoma (FL), offering a highly promising new therapeutic option for patients with R/R indolent B-cell lymphomas. The Phase II clinical study is ongoing.

The study is designed to assess the preliminary anti-tumor efficacy and safety of the combination in this patient population.

These achievements mark significant progress in the program's advancement toward patient validation.

This milestone represents a key step forward in the global clinical development of IMM0306 across autoimmune diseases, bringing a potential breakthrough therapeutic option one step closer to millions of SLE patients worldwide.

This capital increase aims to further strengthen ImmuneCare's financial resources and accelerate the research and development of innovative drugs in cardiovascular diseases, such as pulmonary arterial hypertension (PAH), as well as metabolic diseases. This marks the steady implementation of ImmuneOnco's "oncology + non-oncology" dual-engine strategy.